The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Cell Sheet-Based Gene Therapy Market By 2030 Based On Its 2026 Value?

The market size for cell sheet-based gene therapy has witnessed rapid expansion in recent years. This market is expected to increase from $0.68 billion in 2025 to $0.78 billion in 2026, progressing at a compound annual growth rate (CAGR) of 14.4%. The expansion observed historically is due to increasing advancements in tissue engineering research, the early adoption of regenerative medicine techniques, growth in cell-based therapeutic studies, improvements in gene delivery technologies, and the expansion of translational research initiatives.

The cell sheet-based gene therapy market is projected for significant expansion over the coming years. Its valuation is set to reach $1.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.6%. This anticipated growth stems from factors such as a heightened demand for localized regenerative treatments, an uptick in clinical trials concerning gene-modified cell therapies, broader applications in oncology and cardiology, increased investments in sophisticated tissue engineering, and a growing emphasis on precision regenerative medicine. Key trends anticipated during this period involve the proliferation of multilayered and co-culture cell sheet technologies, an intensified focus on localized gene expression therapies, greater incorporation of regenerative medicine strategies, more frequent utilization of stem-cell derived cell sheets, and an elevated emphasis on tissue integration and long-term viability.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33058&type=smp

What Market Drivers Are Helping Shape The Cell Sheet-Based Gene Therapy Market Expansion?

The increasing occurrence of chronic and degenerative ailments is anticipated to fuel expansion in the cell sheet-based gene therapy market. These long-lasting conditions, encompassing cardiovascular disorders, neurodegenerative diseases, diabetes, and genetic disorders, gradually harm tissues and organs, necessitating ongoing therapeutic treatment. The widespread presence of these health issues is growing because of larger aging populations and extended life expectancies in both developed and emerging economies. Cell sheet-based gene therapy facilitates regenerative treatment methods for chronic and degenerative diseases by allowing localized tissue restoration and continuous gene transfer via layered living cell constructs, which can enhance tissue integration and durable therapeutic results. As an illustration, in April 2025, the International Diabetes Federation (IDF), a non-profit organization based in Belgium, reported that 589 million individuals globally had diabetes in 2024, with this number forecasted to reach 853 million by 2050. Consequently, the growing occurrence of chronic and degenerative diseases is propelling the expansion of the cell sheet-based gene therapy market.

Which Segment Divisions Form The Structure Of The Cell Sheet-Based Gene Therapy Market?

The cell sheet-based gene therapy market covered in this report is segmented –

1) By Cell-Sheet Type: Monolayer Cell-Sheet Type; Co-Culture Cell-Sheet Type; Multilayered Cell-Sheet Type; Other Cell-Sheet Types

2) By Technology Type: Cell Sheet-Based Engineering Techniques; Gene Delivery Methods

3) By Source Type: Autologous; Allogenic; Stem-Cell Derived

4) By Application: Oncology; Ophthalmology; Genetic Disorders; Cardiology; Other Applications

5) By End-User: Hospitals And Clinics; Research And Academic Institutions; Biotech And Pharma Companies; Other End-Users

Subsegments:

1) By Monolayer Cell-Sheet Type: Cardiomyocyte Sheets; Epithelial Cell Sheets; Mesenchymal Stem Cell Sheets; Other Monolayer Cell Sheets

2) By Co-Culture Cell-Sheet Type: Fibroblast + Stem Cell Sheets; Endothelial + Smooth Muscle Cell Sheets; Other Co-Culture Combinations

3) By Multilayered Cell-Sheet Type: Triple-Layered Sheets; Double-Layered Sheets; Other Multilayered Configurations

4) By Other Cell-Sheet Types: Genetically Modified Cell Sheets; Hybrid Cell Sheets; Other Novel Or Experimental Sheets

What Trends Are Affecting The Growth Of The Cell Sheet-Based Gene Therapy Market?

Leading companies operating within the cell sheet-based gene therapy market are concentrating on developing innovative solutions, such as autologous gene-corrected cell sheet products. These aim to enhance regenerative medicine outcomes, improve treatment precision, and achieve long-term tissue repair by combining engineered cells with scaffold-free sheet constructs for targeted gene delivery and wound healing. Autologous gene-corrected cell sheet products describe therapies where a patient’s own cells are genetically modified ex vivo, expanded into sheet constructs that preserve cell-to-cell interactions and extracellular matrix integrity, and then applied directly to damaged tissues to promote functional integration and durable therapeutic effects. For instance, in April 2025, Abeona Therapeutics Inc., a US-based biopharmaceutical company, received Food and Drug Administration (FDA), a US-based federal agency approval for zevaskyn (prademagene zamikeracel), which is designed to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn delivers the functional COL7A1 gene via genetically corrected cell sheets, promotes clinically meaningful wound healing and pain reduction with a single application, and supports sustained type VII collagen expression at wound sites, establishing it as a breakthrough regenerative therapy and a model for future cell sheet-based gene therapy innovations.

Which Companies Form The Competitive Landscape Of The Cell Sheet-Based Gene Therapy Market?

Major companies operating in the cell sheet-based gene therapy market are Hitachi Ltd., Thermo Fisher Scientific, Fujifilm Cellular Dynamics Inc. (FCDI) (FUJIFILM Holdings Corporation), Lonza Group AG, teijin regenet co. ltd., Terumo Corporation, Nikon CeLL innovation Co. Ltd., Rohto Pharmaceutical Co. Ltd., BioBridge Global, AGC Biologics, Shibuya Corporation (Shibuya Kogyo Co. Ltd.), National Resilience Inc., Takara Bio Inc., Japan Tissue Engineering Co. Ltd. (J-TEC), Medipost Co. Ltd., Cell Therapies Pty Ltd, CellSeed Inc., SCTbio, Abeona Therapeutics Inc., Foundation ENEA Tech, Cyto-Facto Inc., ENCELL Co. Ltd.

Access The Complete Cell Sheet-Based Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cell-sheet-based-gene-therapy-market-report

Which Geographic Region Represents The Largest Cell Sheet-Based Gene Therapy Market Share?

North America was the largest region in the cell sheet based gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell sheet-based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Cell Sheet-Based Gene Therapy Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model